Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion type Assertion NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_head.
- NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion wasGeneratedBy ECO_0000203 NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_provenance.
- NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion wasDerivedFrom befree-20150227 NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_provenance.
- NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion SIO_000772 22303460 NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_provenance.
- NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion evidence source_evidence_literature NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_provenance.
- NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_assertion description "[Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493024.RA6aeAHMPZyq0AF-5pPwZVtBog67Xc3RrLUQ5EZXQEvx0130_provenance.